Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
DURHAM, N.C., March 30, 2016 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer, will participate in the 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference being held Thursday, March 31, 2016 at the Apella Event Space at Alexandria Center in New York City. Dr. Schreiber will join a panel discussion starting at 11:00 a.m. ET entitled “Therapeutic Cancer Vaccines: Stimulating the Immune System,” as well as a second panel discussion starting at 4:30 p.m. ET entitled “Combination Immuno-Oncology Themes.”
The conference is hosted by MaidStone Life Sciences, LLC and William Blair & Company, LLC. For more information, please visit http://www.maidstonels.com/conference.html.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
